Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

NCT05609994 is registered in ClinicalTrials.gov with Katy Peters, MD, PhD as lead sponsor.

NCT NCT05609994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05609994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
Lead sponsor
Katy Peters, MD, PhD
Phase
Phase 1
Overall status
Recruiting
Start date
July 15, 2025
Completion date
August 31, 2029
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low grade glioma of brain